Detalles de la búsqueda
1.
Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
Lancet Oncol
; 22(1): 51-65, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33285097
2.
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.
Lancet
; 394(10212): 1929-1939, 2019 11 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-31590988
3.
Durvalumab ± Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden.
Clin Cancer Res
; 30(4): 824-835, 2024 02 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-37801329
4.
Efficacy and Safety of Bevacizumab Biosimilar FKB238 Versus Originator Bevacizumab: Results from AVANA, a Phase III Trial in Patients with Non-Squamous Non-Small-Cell Lung Cancer (non-sq-NSCLC).
BioDrugs
; 35(4): 417-428, 2021 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-34264503
5.
Efficacy, Safety, and Immunogenicity of HLX02 Compared with Reference Trastuzumab in Patients with Recurrent or Metastatic HER2-Positive Breast Cancer: A Randomized Phase III Equivalence Trial.
BioDrugs
; 35(3): 337-350, 2021 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-33826080
6.
Efficacy, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar) versus Reference Bevacizumab in Advanced Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study (STELLA).
BioDrugs
; 35(4): 429-444, 2021 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-33914256
7.
A phase III, randomized, double-blind, multicenter study to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB8 (proposed bevacizumab biosimilar) and reference bevacizumab in patients with metastatic or recurrent nonsquamous non-small cell lung cancer.
Lung Cancer
; 146: 12-18, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32502923
8.
Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study.
Lung Cancer
; 149: 46-52, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32961445
9.
A Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON Study.
Clin Lung Cancer
; 25(3): 266-273.e5, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38584069
Resultados
1 -
9
de 9
1
Próxima >
>>